Xu Wuwu, Liang Ting, Fang Hu, Fu Lu, Deng Dashi, Tan Xiyang, Liu Lisha, Tang Dongdong, Zheng Haoxiang, Ding Qiuxia, Hou Xiuqi, Feng Daquan, Tao Tao, Wu Song
Urology Institute of Shenzhen University, The Third Affiliated Hospital of Shenzhen University (Shenzhen Luohu People's Hospital), Shenzhen University, Shenzhen, 518116, China.
Shenzhen Following Precision Medical Research Institute, Luohu Hospital Group, Shenzhen, 518000, China.
Adv Sci (Weinh). 2025 Aug;12(32):e02774. doi: 10.1002/advs.202502774. Epub 2025 Jun 24.
Cancer-associated fibroblasts (CAFs) play a crucial role in tumor progression, with heterogeneity influencing therapeutic response and prognosis, highlighting their potential as viable targets for treatment. In this study, a novel CAF subgroup, MMP11 mCAF is identified, through single-cell RNA sequencing, which accumulates progressively during bladder cancer progression and is significantly associated with poor prognosis. This cell population regulates the migration of tip endothelial cell clusters (ESM1tEC) via the WNT5A-MCAM signaling axis, and modulates the expression of key transcription factors, SOX18, NFIC, and HOXB9. Additionally, MMP11 mCAFs recruit SPP1 macrophages through CCL11/CCL2, promoting VEGFA secretion, which further enhances the pro-angiogenic activity of ESM1 tECs. Furthermore, interferon-associated basal-like tumor cells secrete BMP2, which induces the expression and activity of NFE2L3, a transcription factor specific to MMP11 mCAFs, promoting WNT5A expression. Mouse experiments confirmed that inhibiting BMP2 can suppress tumor angiogenesis and growth in bladder cancer. Pan-cancer analysis revealed that MMP11 mCAFs are present across various cancer types, including breast cancer, lung adenocarcinoma, gastric cancer, and colorectal cancer. These findings provide insights into the heterogeneity of CAFs and their regulatory role in tumor progression, offering new potential therapeutic targets for CAF-targeted treatments with broad applicability across cancers.
癌症相关成纤维细胞(CAFs)在肿瘤进展中起着关键作用,其异质性影响治疗反应和预后,凸显了它们作为可行治疗靶点的潜力。在本研究中,通过单细胞RNA测序鉴定出一种新型CAF亚群,即MMP11 mCAF,它在膀胱癌进展过程中逐渐积累,且与不良预后显著相关。该细胞群体通过WNT5A - MCAM信号轴调节顶端内皮细胞簇(ESM1tEC)的迁移,并调节关键转录因子SOX18、NFIC和HOXB9的表达。此外,MMP11 mCAFs通过CCL11/CCL2招募SPP1巨噬细胞,促进VEGFA分泌,这进一步增强了ESM1 tECs的促血管生成活性。此外,干扰素相关的基底样肿瘤细胞分泌BMP2,诱导MMP11 mCAFs特异性转录因子NFE2L3的表达和活性,促进WNT5A表达。小鼠实验证实,抑制BMP2可抑制膀胱癌中的肿瘤血管生成和生长。泛癌分析显示,MMP11 mCAFs存在于包括乳腺癌、肺腺癌、胃癌和结直肠癌在内的多种癌症类型中。这些发现为CAFs的异质性及其在肿瘤进展中的调节作用提供了见解,为跨癌症具有广泛适用性的CAF靶向治疗提供了新的潜在治疗靶点。